Mani Mohindru
Chief Executive Officer Cardiff Oncology
Mani Mohindru has served as interim Chief Executive Officer of Cardiff Oncology (Nasdaq: CRDF) since January 2026 and been a director since 2021. She currently also serves as a board director of CytomX Therapeutics (Nasdaq: CTMX) and is a co-founder and board director of Roshon Therapeutics, an early stage private biotech. Previously, she was the CEO and Board Director of Novasenta, as well as CereXis, two private biotechnology companies. She has also held senior leadership positions in public biotech companies, having served as Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc., and Chief Strategy Officer of Curis, Inc. Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity.
Currently, she also serves on the Executive Advisory Board of the CLP Institute of Northwestern University and the Scientific Investment Advisory Committee of the Gates Institute at University of Colorado.
Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and completed B.S. in Human Biology and Masters in Biotechnology from the All India Institute of Medical Sciences, New Delhi, India.
Seminars
- Leveraging PLK1 based synthetic lethality to address RAS mutant metastatic colorectal cancer with a highly selective PLK-1 inhibitor, onvansertib
- Demonstrating potentially practice changing clinical activity and tolerability of onvansertib with FOLFIRI/bev in front line RAS-mut mCRC in a randomized controlled Phase II study
- Defining a clinical path toward approvability through ongoing first line development and combination with a standard chemotherapy backbone in an area of high unmet need with limited advancements
